Wasan Harpreet S - Imperial Coll Healthcare Trust, Hammersmith Hosp

基本信息

浏览量：12

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 42 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

A Plain Language Summary of the Molecular Changes in the Tumors of People with BRAF V600E-mutant Colorectal Cancer in the BEACON Study

Scott Kopetz, Danielle A Murphy,Jie Pu,Fortunato Ciardiello,Jayesh Desai,Eric Van Cutsem,Harpreet Singh Wasan,Takayuki Yoshino, Hedieh Saffari, Xiaosong Zhang, Phineas Hamilton,Tao Xie,Rona Yaeger,Josep Tabernero

Future oncology (London, England)no. 14 (2025): 1713-1723

引用0浏览0WOS引用

The Potential Benefit of Encorafenib Plus Cetuximab with Chemotherapy Compared with Standard of Care in People with BRAF V600E-mutant Metastatic Colorectal Cancer in the BREAKWATER Study: a Plain Language Summary

Scott Kopetz,Takayuki Yoshino,Eric Van Cutsem,Cathy Eng,Tae Won Kim,Harpreet Singh Wasan,Jayesh Desai,Fortunato Ciardiello,Rona Yaeger, Timothy S Maughan, Elena Beyzarov,Xiaoxi Zhang, Graham Ferrier, Xiaosong Zhang,Josep Tabernero

Future oncology (London, England)（2025）

引用0浏览0WOS引用

BREAKWATER: Analysis of First-Line Encorafenib + Cetuximab + Chemotherapy in BRAF V600E-mutant Metastatic Colorectal Cancer

Scott Kopetz,Takayuki Yoshino,Eric Van Cutsem,Cathy Eng,Tae Won Kim,Harpreet Singh Wasan,Jayesh Desai,Fortunato Ciardiello,Rona Yaeger,Timothy S. Maughan,Elena Beyzarov,Xiaoxi Zhang, Graham Ferrier,Xiaosong Zhang,Josep Tabernero

Journal of Clinical Oncologyno. 4_suppl (2025): 16-16

引用0浏览0引用

Encorafenib, Cetuximab and Chemotherapy in BRAF-mutant Colorectal Cancer: a Randomized Phase 3 Trial

Nature Medicine（2025）

引用0浏览0WOSNATURE引用

Encorafenib, Cetuximab, and Mfolfox6 in BRAF-Mutated Colorectal Cancer

Elena Elez,Takayuki Yoshino,Lin Shen,Sara Lonardi,Eric Van Cutsem,Cathy Eng,Tae Won Kim,Harpreet Singh Wasan,Jayesh Desai,Fortunato Ciardiello,Rona Yaeger, Timothy S Maughan, Van K Morris,Christina Wu,Tiziana Usari, Robert Laliberte,Samuel S Dychter, Xiaosong Zhang,Josep Tabernero,Scott Kopetz, BREAKWATER Trial Investigators

The New England journal of medicine (2025)

引用0浏览0WOS引用

Zanidatamab (zani) in Previously Treated HER2+ Biliary Tract Cancer (BTC): Impact on Patient-Reported Pain Outcomes in the Phase 2b HERIZON-BTC-01 Study

Shubham Pant,Jia Fan,Do-Youn Oh,Hye Jin Choi,Jin Won Kim,Heung-Moon Chang,Lequn Bao,Hui-Chuan Sun,Teresa Macarulla, Feng Xie,Jean-Philippe Metges,Jie-Er Ying,John A. Bridgewater,Mohamedtaki Abdulaziz Tejani,Emerson Yu-sheng Chen,Harpreet Singh Wasan,Michel Pierre Ducreux, Jiafang Ma,Phillip M. Garfin,James J. Harding

Journal of Clinical Oncologyno. 3_suppl (2024): 450-450

引用0浏览0引用

Molecular Profiling of BRAF-V600E-mutant Metastatic Colorectal Cancer in the Phase 3 BEACON CRC Trial

Scott Kopetz,Danielle A. Murphy,Jie Pu,Fortunato Ciardiello,Jayesh Desai,Eric Van Cutsem,Harpreet Singh Wasan,Takayuki Yoshino, Hedieh Saffari,Xiaosong Zhang, Phineas Hamilton,Tao Xie,Rona Yaeger,Josep Tabernero

NATURE MEDICINE（2024）

引用3浏览0WOSNATURE引用

Addition of Stereotactic Body Radiotherapy (SBRT) to Systemic Chemotherapy in Locally Advanced Cholangiocarcinoma (CC) (ABC-07): Results from a Randomized Phase II Trial

Maria A. Hawkins,Juan W. Valle,Harpreet Singh Wasan,Mark Harrison,Helen Morement,Prakash Manoharan,Ganesh Radhakrishna,David Eaton,Douglas Brand, Temi Adedoyin, Ka Man Mak, Natasha Hava, Shumona Shelly, Memuna Rashid,Andre Lopes,John A. Bridgewater

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

BREAKWATER: an Open-Label, Multicenter, Randomized, Phase 3 Study, with a Safety Lead-in (SLI), of First-Line (1L) Encorafenib (E) + Cetuximab (C) ± Chemotherapy (CT) Vs Standard-of-care (SOC) CT for BRAF V600E-mutant Metastatic Colorectal Cancer (Mcrc)

Scott Kopetz,Takayuki Yoshino,Tae Won Kim,Harpreet Singh Wasan,Eric Van Cutsem,Fortunato Ciardiello,Timothy S. Maughan,Cathy Eng,Rona Yaeger,Jayesh Desai,Xiaosong Zhang,Tiziana Usari,Ave Mori,Josep Tabernero

Journal of Clinical Oncologyno. 16_suppl (2023)

引用2浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn